The serum concentrations of endoxifen in breast cancer patients with CYP2D6*1/*10(CT) and CYP2D6*10/*10(TT) were shown to be decreased more significantly than those of individuals with wild-type CYP2D6 (10). This evidence concerns the gene CYP2D6 and breast carcinoma.